Long Circulating Liposome Development Service

Long circulating liposome is one of the liposome modified with some polymers, which can make the liposome stay in the blood longer. Based on our accumulation of the expertise and technology in the field of liposomes, Creative Biolabs’ scientific team can provide you with professional solutions for the production and characterization of long circulating liposomes.

Introduction of Long Circulating Liposome

Liposomes have been studied as drug carriers, and many previous studies have proven their effectiveness in encapsulating drugs and reducing the side effects of drugs. In many cases, liposome drugs are carried out through the bloodstream. The stability, clearance and biodistribution of liposomes in blood depend on its composition, size and charge. Conventional liposomes are rapidly removed from the bloodstream through the absorption of mononuclear phagocyte system (MPS) cells. This deficiency can be achieved by grafting liposome phospholipid with polyethylene glycol (PEG) to increase the circulation time and protect the carrier from the regulation and capture of reticuloendothelial system (RES).

Fig.1 PEGylation for long circulating liposome

Functions of Long Circulating Liposome

In general, PEGylation of liposomes is achieved by incubation of PEG reactive derivatives with target parts. The covalent binding of liposome and PEG protects the active part of the immune system of the receptor, thus reducing the immunogenicity and antigenicity. It will also change the physical and chemical properties of the active moiety, including the change of hydrodynamic size, so as to further reduce the renal clearance rate and prolong the circulation time. In addition, it provides hydrophobic drugs with hydrophilicity and reduced dosage frequency. Furthermore, due to the leakage characteristics of tumor vascular system, nanoparticles with prolonged circulation time exhibit enhanced permeation and retention (EPR) and slowly accumulate in the tumor bed. Currently, the application of this technology provides very successful liposome products such as Doxil^® Intravenous injection for the treatment of advanced ovarian cancer, multiple myeloma and HIV-related Kaposi's sarcoma.

Fig.2 Pharmacokinetics of PEGylated liposomes

What We Can Do About Long Circulating Liposome Development?

Reasonable formulation design: our researchers can find the best combination of formula factors through less experiments, and obtain liposomes with expected performance.

Comprehensive characterization: we provide a variety of characterization and analysis services in the development of liposome formulation agents to optimize the performance of the preparation, including visual appearance, size distribution, stability, Zeta potential, lamellarity, entrapment efficiency, and release rate.

Fast turnover time and competitive pricing: our ground-breaking research, objectified working processes, and state-of-the-art equipment all mean that we are able to develop distinctive liposomal formulations and products.

For more details about our services, please directly contact us.

For Research Use Only. Not For Clinical Use